| Purity: | 99 |
|---|---|
| Model Number: | 1195765-45-7 |
| Brand Name: | NJBN STEROID |
| Grade Standard: | Medicine Grade |
| Type: | Vitamins, Amino Acids and Coenzymes |
| Place of Origin: | China (Mainland) |
| EINECS No.: | 200-366-3 |
| MF: | C23H20F3N5O2S2 |
| Other Names: | Dabrafenib |
| CAS No.: | 1195765-45-7 |
| Sample: | Free |
| Market: | Worldwide |
Quick Details
Specifications
Factory Dabrafenib 1195765-45-7 For Skin Cancer 99%
Dabrafenib
Description
Dabrafenib (trade name Tafinlar, GSK2118436) is a drug for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.
The Food and Drug Administration initially approved dabrafenib as a single agent treatment for patients with BRAF V600Emutation-positive advanced melanoma on May 30, 2013.Clinical trial data demonstrated that resistance to dabrafinib and other BRAF inhibitors occurs within 6 to 7 months.To overcome this resistance, the BRAF inhibitor dabrafenib was combined with the MEK inhibitor trametinib.On January 8, 2014, the FDA approved this combination of dabrafenib and trametinib for BRAF V600E/K-mutant metastatic melanoma.
Application
Dabrafenib is used to treat a certain type of melanoma (a type of skin cancer) that cannot be treated with surgery or that has spread to other parts of the body. Dabrafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
Dabrafenib
| Product name | Dabrafenib |
| Synonyms | Dabrafenib;N-[3-[5-(2-Amino-4-pyrimidinyl)-2-(tert-butyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;Dabrafenib free base(GSK2118436A);Dabrafenib(GSK2118436);GSK2118436A;Dabrafenib (GSK2118436);Dabrafenib KB-57246;Debrafenib API |
| CAS NO | 1195765-45-7 |
| MF | C23H20F3N5O2S2 |
| MW | 519.5624096 |
| EINECS | 200-366-3 |
| Appearance | White to slightly yellowish-white crystalline |
| Assay | 99%min |
| Storage | Shading, confined preservation |
| Brand | NJBN STEROID |
| Delivery | EMS, DHL, TNT, FedEx, UPS |
| Delivery time | within 24 hours upon receipt of payment |
| Product Category | Raf B protein kinase inhibitor;inhibitor;MAPK;Inhibitors |
Description
Dabrafenib (trade name Tafinlar, GSK2118436) is a drug for the treatment of cancers associated with a mutated version of the gene BRAF. Dabrafenib acts as an inhibitor of the associated enzyme B-Raf, which plays a role in the regulation of cell growth. Dabrafenib has clinical activity with a manageable safety profile in clinical trials of phase 1 and 2 in patients with BRAF(V600)-mutated metastatic melanoma.
The Food and Drug Administration initially approved dabrafenib as a single agent treatment for patients with BRAF V600Emutation-positive advanced melanoma on May 30, 2013.Clinical trial data demonstrated that resistance to dabrafinib and other BRAF inhibitors occurs within 6 to 7 months.To overcome this resistance, the BRAF inhibitor dabrafenib was combined with the MEK inhibitor trametinib.On January 8, 2014, the FDA approved this combination of dabrafenib and trametinib for BRAF V600E/K-mutant metastatic melanoma.
Application
Dabrafenib is used to treat a certain type of melanoma (a type of skin cancer) that cannot be treated with surgery or that has spread to other parts of the body. Dabrafenib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps stop the spread of cancer cells.
